[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100543932":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":42,"collaborators":11,"id":44,"slug":11,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":11,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":11,"enrollmentInfo":52,"targetDuration":11,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":11,"overallStatus":28,"whyStopped":11,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"Peking Union Medical College Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"intracranial tumor","EXPERIMENTAL",null,[13],"Diagnostic Test: 99mTc-CNDG SPECT\u002FCT",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DIAGNOSTIC_TEST","99mTc-CNDG SPECT\u002FCT","FDG-PET and 99mTc-CNDG will be performed within 2 weeks before surgery.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Zhaohui Zhu","CONTACT","01069154241","13611093752@163.com",[27],{"facility":5,"status":28,"city":29,"state":30,"zip":31,"country":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"RECRUITING","Beijing","Beijing Municipality","100730","China",{"type":34,"coordinates":35},"Point",[36,37],116.39723,39.9075,{"lat":37,"lon":36},[40],{"name":22,"role":23,"phone":41,"phoneExt":11,"email":25},"010-69154241",{"type":43,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100543932",false,"NCT06362304","99mTc-CNDG SPECT\u002FCT in Brain Tumors","Application of 99mTc-CNDG SPECT\u002FCT Imaging in the Diagnosis of Brain Tumors","Inclusion Criteria:\n\n* Patients with clinical diagnosis of brain tumor;\n* Be at least 18 years old;\n* The final pathological results could be obtained by surgery or biopsy;\n* Informed consent and the ability to be followed up;\n* Those who did not meet the exclusion criteria.\n\nExclusion Criteria:\n\n* Insulin-dependent diabetes mellitus or fasting blood glucose \\>7 mmol\u002FL before 99mTc-CNDG injection;\n* Severe liver or kidney disease (serum creatinine level \\>3.0mg\u002FdL or any liver enzyme level ≥ 5 times the upper limit of normal);\n* Severe hypersensitivity or hypersensitivity to radiocontrast agents;\n* Claustrophobia (inability to undergo SPECT\u002FCT or PET\u002FCT scans);\n* Patients receiving radiotherapy and chemotherapy;\n* Being pregnant or breastfeeding.","ALL","18 Years",{"count":53,"type":54},30,"ESTIMATED","INTERVENTIONAL",[57],"NA","The goal of this clinical trial is to evaluate the value of 99mTc-CNDG for diagnosis of brain tumors by comparing it with 18F-FDG-PET. The main questions it aims to answer are:\n\n1. What is the diagnostic consistency between 99mTc-CNDG and 18F-FDG?\n2. What is the correlation between the SUVmax value of 99mTc-CNDG and tumor type?\n\nParticipants will:\n\nReceive18F-FDG-PET and 99mTc-CNDG examination within 2 weeks before surgery. Obtain pathological diagnosis by surgery or biopsy as the gold standard.",[60],"Intracranial Tumor","2024-11-21",{"date":63,"type":64},"2024-11-25","ACTUAL",{"date":66,"type":64},"2024-04-20",{"date":68,"type":54},"2025-04",{"name":5,"class":6},1]